Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Narendranath Epperla; Kwang W. Ahn; Carlos Litovich; Sairah Ahmed; Minoo Battiwalla; Jonathon B. Cohen; Parastoo Dahi; Nosha Farhadfar; Umar Farooq; Cesar O. Freytes; Nilanjan Ghosh; Bradley Haverkos; Alex Herrera; Mark Hertzberg; Gerhard Hildebrandt; David Inwards; Mohamed A. Kharfan-Dabaja; Farhad Khimani; Hillard Lazarus; Aleksandr Lazaryan; Lazaros Lekakis; Hemant Murthy; Sunita Nathan; Taiga Nishihori; Attaphol Pawarode; Tim Prestidge; Praveen Ramakrishnan; Andrew R. Rezvani; Rizwan Romee; Nirav N. Shah; Ana Sureda; Timothy S. Fenske; Mehdi Hamadani

doi:10.1186/s13045-018-0696-z

$Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis$

Journal article

Open access

Peer reviewed

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Narendranath Epperla, Kwang W. Ahn, Carlos Litovich, Sairah Ahmed, Minoo Battiwalla, Jonathon B. Cohen, Parastoo Dahi, Nosha Farhadfar, Umar Farooq, Cesar O. Freytes, …

Journal of hematology and oncology, Vol.12(1), pp.6-6

01/10/2019

DOI: 10.1186/s13045-018-0696-z

PMCID: PMC6329157

PMID: 30630534

Files and links (1)

url

https://doi.org/10.1186/s13045-018-0696-zView

Published (Version of record) Open Access

Abstract

Background: There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. Methods: We evaluated 249 adult AITL patients who received their first allo-HCT during 2000-2016. Results: The median patient age was 56 years (range = 21-77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4-170 months). The cumulative incidence of grade 2-4 and grade 3-4 acute GVHD at day 180 were 36% (95% CI = 30-42) and 12 (95% CI = 8-17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43-56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14-24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16-27), 49% (95% CI = 42-56), and 56% (95% CI = 49-63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08-2.77), while KPS < 90% was associated with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75-6.87). Conclusion: Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.

Allogeneic transplantation

Angioimmunoblastic T-cell lymphoma

GVL effects

Details

Title: Subtitle: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
Creators: Narendranath Epperla - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Kwang W. Ahn - Center for International Blood and Marrow Transplant Research
Carlos Litovich - Center for International Blood and Marrow Transplant Research
Sairah Ahmed - 1515 Holcombe Boulevard, Houston, TX 77030 USA
Minoo Battiwalla - Sarah Cannon
Jonathon B. Cohen - Emory University
Parastoo Dahi - Memorial Sloan Kettering Cancer Center
Nosha Farhadfar - University of Florida Health
Umar Farooq - University of Iowa Hospitals and Clinics
Cesar O. Freytes - CHRISTUS Transplant Institute
Nilanjan Ghosh - Levine Cancer Institute
Bradley Haverkos - University of Colorado Hospital
Alex Herrera - City Of Hope National Medical Center
Mark Hertzberg - Prince of Wales Hospital
Gerhard Hildebrandt - Albert B. Chandler Hospital
David Inwards - Mayo Clinic in Florida
Mohamed A. Kharfan-Dabaja - Mayo Clinic in Florida
Farhad Khimani - Moffitt Cancer Center
Hillard Lazarus - Case Western Reserve University
Aleksandr Lazaryan - Moffitt Cancer Center
Lazaros Lekakis - Case Western Reserve University
Hemant Murthy - Florida College
Sunita Nathan - Rush University Medical Center
Taiga Nishihori - Moffitt Cancer Center
Attaphol Pawarode - University of Michigan
Tim Prestidge - Starship Children's Health
Praveen Ramakrishnan - Southwestern Medical Center
Andrew R. Rezvani - Stanford Health Care
Rizwan Romee - Dana-Farber Cancer Institute
Nirav N. Shah - Medical College of Wisconsin
Ana Sureda - Duran i Reynals Hospital
Timothy S. Fenske - Medical College of Wisconsin
Mehdi Hamadani - Medical College of Wisconsin
Resource Type: Journal article
Publication Details: Journal of hematology and oncology, Vol.12(1), pp.6-6
DOI: 10.1186/s13045-018-0696-z
PMID: 30630534
PMCID: PMC6329157
NLM abbreviation: J Hematol Oncol
ISSN: 1756-8722
eISSN: 1756-8722
Publisher: BioMed Central
Language: English
Date published: 01/10/2019
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359807102771

Metrics

27 Record Views

32 Times Cited - Web of Science